A progressive liver condition affects thousands of Americans, but early symptoms are often dismissed as everyday ailments. Learn the critical warning signs of Primary biliary cholangitis (PBC) and ...

FDA approves Ipsen's Iqirvo for primary biliary cholangitis, ending a 10-year hiatus in new therapies for the rare cholestatic liver disease.

FDA approves Gilead's Livdelzi for primary biliary cholangitis, setting up a contest with Ipsen's recent launch Iqirvo in the second-line setting.

The global prevalence of primary biliary cholangitis (PBC) has increased, particularly in the Western Pacific region of the world, according to study results published in Clinical Gastroenterology and ...